Theracryf Plc (TCF) Ordinary 0.25p
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
Contact details
Important dates
General stock information
- EPIC:
- TCF
- ISIN:
- GB00BSVYN304
- Market cap:
- £3.31 million
- Shares in issue:
- 427.35 million
- Sector:
- Pharmaceuticals & Biotechnology
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.